Redx Pharma logo

REDA - Redx Pharma Share Price

n/a 0.0  0.0%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 1806
Bullish
Bearish
Unlock REDA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 September 2020, RedxPharma PLC revenues increased 82% to £5.7M. Net lossincreased from £4.3M to £9.2M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsRecovery of derecognised asset decrease from £869K (income)to £0K, Share based compensation increase from £45K to£568K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

REDA Revenue Unlock REDA Revenue

Net Income

REDA Net Income Unlock REDA Revenue

Normalised EPS

REDA Normalised EPS Unlock REDA Revenue

PE Ratio Range

REDA PE Ratio Range Unlock REDA Revenue

Dividend Yield Range

REDA Dividend Yield Range Unlock REDA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
REDA EPS Forecasts Unlock REDA Revenue
Profile Summary

Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
Incorporated September 7, 2010
Public Since March 27, 2015
No. of Shareholders: n/a
No. of Employees: 52
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange
Shares in Issue
Free Float (0.0%)
Eligible for
ISAs
SIPPs
REDA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for REDA
Upcoming Events for REDA
Similar to REDA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.